Genfit raises €4.4M Series A round
29 March 2017· Loos, France· health, biotech, drug_development, diagnostics, b2b
The proceeds will be used to progress the lead candidate, VS-01, into a Phase I/II clinical trial targeting hepatic encephalopathy in acute-on-chronic liver-failure, as well as to further develop the company's preclinical pipeline.
Investors
LeadRedalpine Venture Partners
Also participating
Zürcher KantonalbankAltus PartnersHealthEquityOccident Group
About Genfit
Stage
Series B
Headquarters
Loos, France
Founded
1999
Team Size
51–200
Sectors
healthbiotechdrug_developmentdiagnosticsb2b